• Q2 report due on Thursday, 17 August • Solid performance in segments, OH costs still weigh • Needs...
Redeye retains its positive view of Proact following a solid Q2 report, with the positive highlights...
Redeye shortly comments on CLS’ announcement regarding its directed offset issue to underwriters.
Stigande räntekostnader pressar vinsten och nu ligger fokus på att stärka likviditeten.
Redeye is intrigued by today’s news that Saniona has entered into a collaboration agreement with the...
Bra resultat givet utmanande förutsättningar Bokusgruppen rapporterade EBITA på -23,5 mkr, att jämfö...
-8% organisk tillväxt men fortsatta förvärv.. Byggefterfrågan försämrades ytterligare under kvartale...
Den förvaltande delen av bolaget fortsätter att leverera Hyresintäkterna i kvartalet uppgick till 1 ...
APAC and Consumables delivers another strong quarter with double digit growth.
• Q2 report due on Thursday, 27 July • Some but not full effect from cost savings programme • Tradin...
Finnair reports Q2 results on Jul 21. The recent profit warning indicates this year will already see...
This morning, Vow announced that the company’s record USD 27m contract for a Biochar/renewable energ...
Ahead of Atria’s Q2, due on 20 July, we keep our estimates intact.
ChromoGenics AB's rights issue, announced on May 17, 2023, ended on July 12, 2023.
Redeye retains its positive view of Formpipe following a Q2 report largely matching our expectations...
Redeye retains its positive view of Addnode following the Q2 report, confirming what we expected giv...
Redeye remains confident on the case although Q2 numbers were a bit below our estimates.
• Overstocked clients to hamper recovery in H2'23e • 25% q-o-q order booking decline • '23e-'25e adj...
Redeye gives a short comment on Ependion's Q2 2023, which came in exactly in line on EBIT, and close...
